The Korean journal of internal medicine

  • 제28권5호
  • /
  • Pages.587-593
  • /
  • 2013
  • /
  • 1226-3303(pISSN)
  • /
  • 2005-6648(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

Encapsulating peritoneal sclerosis: case series from a university center

  • Hong, Kyung-Deuk (Department of Internal Medicine, Kyungpook National University Hospital) ;
  • Bae, Ji Hea (Department of Radiology, Kyungpook National University Hospital) ;
  • Jang, Yun-Jin (Department of Radiology, Kyungpook National University Hospital) ;
  • Jung, Hee-Yeon (Department of Internal Medicine, Kyungpook National University Hospital) ;
  • Cho, Jang-Hee (Department of Internal Medicine, Kyungpook National University Hospital) ;
  • Choi, Ji-Young (Department of Internal Medicine, Kyungpook National University Hospital) ;
  • Kim, Chan-Duck (Department of Internal Medicine, Kyungpook National University Hospital) ;
  • Kim, Yong-Lim (Department of Internal Medicine, Kyungpook National University Hospital) ;
  • Park, Sun-Hee (Department of Internal Medicine, Kyungpook National University Hospital)
  • 투고 : 2012.06.26
  • 심사 : 2012.07.30
  • 발행 : 2013.09.01
⟨ 이전 논문 다음 논문 ⟩

초록

Background/Aims: Encapsulating peritoneal sclerosis (EPS) is an often-fatal complication of long-term peritoneal dialysis (PD). We here report the clinical features of EPS in Korean PD patients from a single university center. Methods: The data were collected retrospectively from 606 PD patients at Kyungpook National University Hospital, between August 2001 and August 2011. The diagnosis of EPS was based on clinical signs and symptoms, and confirmed by radiological findings. Results: Eight patients (1.3%, four males) were diagnosed with EPS. The mean age of the patients was 48.5 years (range, 33 to 65). The mean duration of PD was 111.8 months (range, 23 to 186). All patients except for one had three or more episodes of peritonitis. Seven patients were diagnosed with EPS after stopping PD, and only one stayed on PD after initial diagnosis and treatment. Total parenteral nutrition and corticosteroids, in addition to tamoxifen therapy, were used to treat most of the patients, and one patient underwent surgery (adhesiolysis). The overall mortality rate was 50%. Conclusions: EPS is a serious, life-threatening complication in patients on longterm PD. To reduce the incidence and mortality rate of EPS, careful monitoring and early diagnosis is needed.

키워드

참고문헌

  1. Brown EA, Van Biesen W, Finkelstein FO, et al. Length of time on peritoneal dialysis and encapsulating peritoneal sclerosis: position paper for ISPD. Perit Dial Int 2009;29:595-600.
  2. Rigby RJ, Hawley CM. Sclerosing peritonitis: the experience in Australia. Nephrol Dial Transplant 1998;13:154- 159. https://doi.org/10.1093/ndt/13.1.154
  3. Kawanishi H, Kawaguchi Y, Fukui H, et al. Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. Am J Kidney Dis 2004;44:729-737. https://doi.org/10.1053/j.ajkd.2004.06.020
  4. Johnson DW, Cho Y, Livingston BE, et al. Encapsulating peritoneal sclerosis: incidence, predictors, and outcomes. Kidney Int 2010;77:904-912. https://doi.org/10.1038/ki.2010.16
  5. Kawaguchi Y, Kawanishi H, Mujais S, Topley N, Oreopoulos DG. Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment: International Society for Peritoneal Dialysis Ad Hoc Committee on ultrafiltration management in peritoneal dialysis. Perit Dial Int 2000;20 Suppl 4:S43-S55.
  6. Kawanishi H, Watanabe H, Moriishi M, Tsuchiya S. Successful surgical management of encapsulating peritoneal sclerosis. Perit Dial Int 2005;25 Suppl 4:S39-S47.
  7. Ti JP, Al-Aradi A, Conlon PJ, Lee MJ, Morrin MM. Imaging features of encapsulating peritoneal sclerosis in continuous ambulatory peritoneal dialysis patients. AJR Am J Roentgenol 2010;195:W50-W54. https://doi.org/10.2214/AJR.09.3175
  8. Tarzi RM, Lim A, Moser S, et al. Assessing the validity of an abdominal CT scoring system in the diagnosis of encapsulating peritoneal sclerosis. Clin J Am Soc Nephrol 2008;3:1702-1710. https://doi.org/10.2215/CJN.01820408
  9. Korte MR, Sampimon DE, Lingsma HF, et al. Risk factors associated with encapsulating peritoneal sclerosis in Dutch EPS study. Perit Dial Int 2011;31:269-278. https://doi.org/10.3747/pdi.2010.00167
  10. Lee HY, Kim BS, Choi HY, et al. Sclerosing encapsulating peritonitis as a complication of long-term continuous ambulatory peritoneal dialysis in Korea. Nephrology (Carlton) 2003;8 Suppl:S33-S39. https://doi.org/10.1046/j.1440-1797.8.s.11.x
  11. Summers AM, Clancy MJ, Syed F, et al. Single-center experience of encapsulating peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal failure. Kidney Int 2005;68:2381-2388. https://doi.org/10.1111/j.1523-1755.2005.00701.x
  12. Brown MC, Simpson K, Kerssens JJ, Mactier RA; Scottish Renal Registry. Encapsulating peritoneal sclerosis in the new millennium: a national cohort study. Clin J Am Soc Nephrol 2009;4:1222-1229. https://doi.org/10.2215/CJN.01260209
  13. Kawanishi H, Moriishi M. Epidemiology of encapsulating peritoneal sclerosis in Japan. Perit Dial Int 2005;25 Suppl 4:S14-S18.
  14. Chin AI, Yeun JY. Encapsulating peritoneal sclerosis: an unpredictable and devastating complication of peritoneal dialysis. Am J Kidney Dis 2006;47:697-712. https://doi.org/10.1053/j.ajkd.2005.12.049
  15. Afthentopoulos IE, Passadakis P, Oreopoulos DG, Bargman J. Sclerosing peritonitis in continuous ambulatory peritoneal dialysis patients: one center's experience and review of the literature. Adv Ren Replace Ther 1998;5:157-167. https://doi.org/10.1016/S1073-4449(98)70028-7
  16. Sawai T, Tomono K, Yanagihara K, et al. Role of coagulase in a murine model of hematogenous pulmonary infection induced by intravenous injection of Staphylococcus aureus enmeshed in agar beads. Infect Immun 1997;65:466-471.
  17. Kocianova S, Vuong C, Yao Y, et al. Key role of polygamma- DL-glutamic acid in immune evasion and virulence of Staphylococcus epidermidis. J Clin Invest 2005;115:688-694. https://doi.org/10.1172/JCI200523523
  18. Moriishi M, Kawanishi H, Tsuchiya S. Impact on peritoneal membrane of use of icodextrin-based dialysis solution in peritoneal dialysis patients. Adv Perit Dial 2006;22:24-28.
  19. Habib AM, Preston E, Davenport A. Risk factors for developing encapsulating peritoneal sclerosis in the icodextrin era of peritoneal dialysis prescription. Nephrol Dial Transplant 2010;25:1633-1638. https://doi.org/10.1093/ndt/gfp677
  20. Dobbie JW. Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Perit Dial Int 1992;12:14-27.
  21. Kyuden Y, Ito T, Masaki T, Yorioka N, Kohno N. Tgfbeta1 induced by high glucose is controlled by angiotensin- converting enzyme inhibitor and angiotensin II receptor blocker on cultured human peritoneal mesothelial cells. Perit Dial Int 2005;25:483-491.
  22. Noh H, Ha H, Yu MR, Kim YO, Kim JH, Lee HB. Angiotensin II mediates high glucose-induced TGF-beta1 and fibronectin upregulation in HPMC through reactive oxygen species. Perit Dial Int 2005;25:38-47.
  23. Korte MR, Sampimon DE, Betjes MG, Krediet RT. Encapsulating peritoneal sclerosis: the state of affairs. Nat Rev Nephrol 2011;7:528-538. https://doi.org/10.1038/nrneurol.2011.107
  24. Kuriyama S, Tomonari H. Corticosteroid therapy in encapsulating peritoneal sclerosis. Nephrol Dial Transplant 2001;16:1304-1305. https://doi.org/10.1093/ndt/16.6.1304
  25. Eltoum MA, Wright S, Atchley J, Mason JC. Four consecutive cases of peritoneal dialysis-related encapsulating peritoneal sclerosis treated successfully with tamoxifen. Perit Dial Int 2006;26:203-206.
  26. Lafrance JP, Letourneau I, Ouimet D, et al. Successful treatment of encapsulating peritoneal sclerosis with immunosuppressive therapy. Am J Kidney Dis 2008;51:e7-e10. https://doi.org/10.1053/j.ajkd.2007.07.036
  27. Balasubramaniam G, Brown EA, Davenport A, et al. The Pan-Thames EPS study: treatment and outcomes of encapsulating peritoneal sclerosis. Nephrol Dial Transplant 2009;24:3209-3215. https://doi.org/10.1093/ndt/gfp008
  28. Kawanishi H; Long-Term Peritoneal Dialysis Study Group. Encapsulating peritoneal sclerosis in Japan: prospective multicenter controlled study. Perit Dial Int 2001;21 Suppl 3:S67-S71.

피인용 문헌

  1. A case of acute EPS with local cocoon formation in a patient on peritoneal dialysis vol.4, pp.2, 2013, https://doi.org/10.1007/s13730-015-0178-x
  2. Successful Treatment of Encapsulating Peritoneal Sclerosis by Hemodialysis and Peritoneal Lavage Using Dialysate Containing Dissolved Hydrogen vol.35, pp.1, 2015, https://doi.org/10.3747/pdi.2013.00255
  3. Encapsulating peritoneal sclerosis as a late complication of peritoneal dialysis vol.4, pp.3, 2015, https://doi.org/10.1016/j.amsu.2015.03.006
  4. Two Cases of Bacterial Peritonitis in Encapsulating Peritoneal Sclerosis vol.89, pp.3, 2013, https://doi.org/10.3904/kjm.2015.89.3.346
  5. Combined surgical and immunosupressive therapy for encapsulating peritoneal sclerosis vol.26, pp.6, 2013, https://doi.org/10.4103/0971-4065.177139
  6. Length of Time on Peritoneal Dialysis and Encapsulating Peritoneal Sclerosis — Position Paper for ISPD: 2017 Update vol.37, pp.4, 2013, https://doi.org/10.3747/pdi.2017.00018
  7. Outcomes of the surgical management of encapsulating peritoneal sclerosis: A case series from a single center in Korea vol.38, pp.4, 2019, https://doi.org/10.23876/j.krcp.19.044